Login to Your Account



Immunotherapy's next move: combinations, sequencing, stopping

By Karen Pihl-Carey
Staff Writer

Friday, September 8, 2017

MADRID, Spain – The rapid approval of immunotherapies that began a decade ago has oncologists and researchers brainstorming ideas for patient benefit, all asking the same question: What's next?

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription